Helissey C, Parnot C, Rivière C, Duverger C, Schernberg A, Becherirat S, Picchi H, Le Roy A, Vuagnat P, Pristavu R, Vanquaethem H, Brureau L
Clinical Research Unit, Department of Oncology, Military Hospital Begin, Saint-Mandé, France.
Department of Medical Oncology, Military Hospital Begin, Saint-Mandé, France.
Front Digit Health. 2023 May 8;5:1104700. doi: 10.3389/fdgth.2023.1104700. eCollection 2023.
The benefits of Electronic Patient -Reported Outcomes (e-PRO) for telemonitoring are well established, allowing early detection of illnesses and continuous monitoring of patients. The primary objective of the PROTECTY study was to assess the compliance with patient use of the telemonitoring platform Cureety. An exploratory objective was to assess if the first-month health status is a prognostic factor of progression free-survival (PFS) and overall survival (OS) for prostate cancer patient.
This prospective study was conducted at the Military Hospital Bégin on prostate cancer patients. Patients were allowed to respond to a symptomatology questionnaire based on CTCAE v.5.0, personalized to their pathology and treatment. An algorithm evaluates the health status of the patient based on the reported adverse events, with a classification into 2 different states: Good Health Status (GHS) and Poor Health status (PHS).
Sixty-one patients were enrolled between July 1st, 2020 and September 30th, 2021. The median age was 74.0 (range 58.0-94.0). 78% presented a metastatic stage, and the most represented cancer was mHSPC. Overall, 2,457 questionnaires were completed by the patients, 4.0% resulted in a health classification in to monitor or critical state. 87% of patients were classified in the GHS group. The compliance was 72% in the overall population during the first month, 71% in GHS group and 75% in PHS group. The median follow-up was 8 months. PFS at 6 months was 84% in GHS group vs. 57% in PHS group, = 0.19. OS at 6 months was 98% in GHS group vs. 83% in PHS group, = 0.31.
Our study showed that compliance was satisfactory. The feasibility of remote monitoring for prostate cancer patients means that they should benefit from its implementation. Our study is also the first to assess the correlation between treatment tolerance and survival. The initial results suggest that e-PRO assessment could help identify in the early stages the patients that require further health assessment and potential therapeutic changes. While further follow-up of more patients will be required, our study highlights the importance of e-PRO in cancer patient care.
电子患者报告结局（e-PRO）用于远程监测的益处已得到充分证实，它能够实现疾病的早期检测以及对患者的持续监测。PROTECTY研究的主要目的是评估患者对远程监测平台Cureety的使用依从性。一个探索性目的是评估前列腺癌患者的首月健康状况是否为无进展生存期（PFS）和总生存期（OS）的预后因素。
这项前瞻性研究在贝金军事医院对前列腺癌患者开展。患者被允许根据CTCAE v.5.0填写一份针对其病理和治疗情况的症状问卷。一种算法根据报告的不良事件评估患者的健康状况，并将其分为两种不同状态：良好健康状态（GHS）和不良健康状态（PHS）。
在2020年7月1日至2021年9月30日期间共纳入61例患者。中位年龄为74.0岁（范围58.0 - 94.0岁）。78%的患者处于转移阶段，最常见的癌症类型是转移性去势敏感性前列腺癌（mHSPC）。总体而言，患者共完成了2457份问卷，4.0%的问卷结果显示健康状况被分类为需监测或危急状态。87%的患者被归类到GHS组。总体人群首月的依从性为72%，GHS组为71%，PHS组为75%。中位随访时间为8个月。GHS组6个月时的PFS为84%，而PHS组为57%，P = 0.19。GHS组6个月时的OS为98%，PHS组为83%，P = 0.31。
我们的研究表明依从性令人满意。前列腺癌患者远程监测的可行性意味着他们应能从其实施中获益。我们的研究也是首个评估治疗耐受性与生存之间相关性的研究。初步结果表明，e-PRO评估有助于在早期识别需要进一步健康评估和潜在治疗调整的患者。虽然需要对更多患者进行进一步随访，但我们的研究凸显了e-PRO在癌症患者护理中的重要性。
